Changes in Hong Kong stocks | Pharmaceutical Biotech (02269) rose more than 5%, leading the CRO concept financing environment, which is expected to improve the market and continue to monitor the progress of the Aesthetic Biology Act
CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
Hong Kong Stock Afternoon Review | The three major indices of Hong Kong stocks pulled back, and the Tech Index fell nearly 2%; PV stocks reversed the market, and GCL Technology rose more than 6%
Technology Network stocks declined; Bilibili fell more than 6%, NetEase fell more than 4%, Kuaishou and Meituan fell nearly 4%; as concept stocks declined, Huazhu Group fell more than 3%, and Jiumaojiu fell nearly 3%.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Zhitong Hong Kong Stock Exchange Unravels | A-shares make up gains and continues to boost Hong Kong stocks need to be wary of attacking Rafah
The current problem with Hong Kong stocks is nothing more than a matter of profit digestion, but under the stimulus of the money-making effect, the entry of incremental capital is expected to form a hedge
Hong Kong stocks closed (05.06) | The Hang Seng Index closed up 0.55% to reap the Shilianyang CRO concept, strong high-speed rail infrastructure stocks, and domestic housing stocks fell across the board
The US non-farm payrolls data for April fell short of expectations, and expectations of market interest rate cuts rebounded somewhat. Hong Kong stocks bottomed out and rebounded today. The three major indices all turned red. The Hang Seng Index successfully reaped 10 consecutive days, and the Hengke Index also reached the 4,000 point mark.
Hong Kong Stock Afternoon Review | The three major indices fluctuated slightly, pharmaceutical stocks strengthened against the market, and Pharmaceutical Biotech rose more than 5%
Most Technet stocks weakened, with Kuaishou falling nearly 2%, Meituan, Xiaomi, and Bilibili falling more than 1%; travel and tourism stocks generally rising, with Ctrip Group rising nearly 3%, Hong Kong China Travel up more than 2%, and Tongcheng Travel up more than 1%.
Intraday Overview | The three major indices of Hong Kong stocks weakened slightly, and the pharmaceutical outsourcing concept rose against the market
Road transport stocks strengthened; Guangzhou-Shenzhen Railway shares rose more than 9%, Anhui Wantong Expressway rose more than 6%; domestic housing stocks collectively pulled back, Agile Group fell more than 6%, and Midea Real Estate fell more than 5%.
Changes in Hong Kong stocks | Yao Ming Biotech rose more than 7% to lead CRO concept stocks. The Federal Reserve may still cut interest rates during the year, and overseas demand is expected to resume
On May 6, CRO concept stocks had the highest gains in early trading. As of press release, Tiger Pharmaceuticals (03347) rose 6.82% to HK$36.8; Pharmaceutical Biotech (02269) rose 5.87% to HK$36.45; Kanglong Chemical (03759) rose 4.92% to HK$10.44; and Pharmaceuticals Kangde (02359) rose 3.14% to HK$37.75.
Hong Kong CXO concept stocks fluctuated higher, and Pharmaceutical Biotech rose more than 8%
Gelonghui, May 6 | Yao Ming Biotech rose more than 8%, Tiger Pharmaceuticals and Kanglong Chemical rose more than 5%, while Pharmaceutical Kangde and Kingsry Biotech had the highest gains.
Hong Kong biotechnology stocks continued to rise, with Pharmaceuticals up more than 5%, Pharmaceutical and Junshi Biotech up more than 4%, Goli Pharmaceuticals up more than 3%, and Tiger Pharmaceuticals up more than 2%.
Hong Kong biotechnology stocks continued to rise, with Pharmaceuticals up more than 5%, Pharmaceutical and Junshi Biotech up more than 4%, Goli Pharmaceuticals up more than 3%, and Tiger Pharmaceuticals up more than 2%.
Tiger Pharmaceuticals (03347) plans to spend 500 million to 1 billion yuan to buy back no less than 13.8889 million shares
Tiger Pharmaceuticals (03347) issued an announcement. The company announced on February 6, 2024 and April 12, 2024, respectively...
Tiger Pharmaceuticals (03347) will pay a final dividend of 5.68 yuan for 10 shares on July 31
According to Zhitong Finance App, Tiger Pharmaceuticals (03347) announced that the company will pay a final dividend of 5.68 yuan for 10 shares on July 31, 2024.
泰格醫藥:2023年股東週年大會通告
泰格醫藥:2023年度報告
TIGERMED(300347):MEANINGFUL DEMAND RECOVERY IN 1Q24
Tigermed reported 1Q24 revenue of RMB1,660mn, down 8.0% YoY, and attributable re
Tiger Pharmaceuticals (300347) Company Information Update Report: Performance is under phased pressure and is expected to gradually recover in 2024
Performance was under phased pressure. Ongoing orders grew steadily in 2024Q1. The company achieved operating income of 1,660 billion yuan, a year-on-year decrease of 8.00%; net profit to mother was 235 million yuan, a year-on-year decrease of 58.65%; after deduction, net income returned to mother
Tiger Pharmaceuticals (300347): Short-term demand under pressure is expected to improve to drive a recovery in performance
Guide to this report: The company released its 2024 quarterly report. The performance was slightly lower than expected. The performance declined due to the base effect and weakening order demand. It is expected that the 24-year results will pick up quarterly as demand improves. Key investment points: maintaining “increasing holdings”
Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) last week released its latest first-quarter, and things did not turn out so great for shareholders. The analysts look to hav
Tiger Pharmaceuticals (300347): Multiple factors disrupt Q1 and expect innovative drug policies to boost the gradual recovery of the industry
Incident: The company released its 2024 quarterly report. In the first quarter of 2024, the company achieved operating income of 1,660 million yuan, a slight decrease of 8.00% over the previous year; net profit to mother was 235 million yuan, a decrease of 58.65% over the previous year; withheld
A quick look at the Hong Kong market | Hong Kong stocks explode! The Ke Index rose nearly 5%; domestic housing stocks and auto stocks improved, Sunac China rose more than 15%, and Xiaopeng Motors rose nearly 9%
Technet stocks performed brilliantly. Kuaishou rose more than 7%, JD rose nearly 6%; biotech stocks generally rose, Tiger Pharmaceuticals rose more than 8%, and Pharmaceutical Biotech rose nearly 6%.
No Data